TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that the Nasdaq Hearings Panel (the “Panel”) has granted EpiCept’s request for continued listing on the Nasdaq Stock Market, subject to EpiCept evidencing, on or prior to September 30, 2011, a closing bid price of $1.00 or more for a minimum of 10 consecutive trading days, which would bring EpiCept back into compliance with Nasdaq Listing Rule 5550(a)(2). In making this determination, the Panel cited the Company’s cash position, the expectation that near-term clinical, regulatory and/or commercial milestones can support compliance with the continued listing requirements of the Nasdaq Capital Market, and the Company’s demonstrated ability to raise non-equity capital.
